Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in stage III melanoma.
Anthony J. Olszanski, MD, RPh
Advertisement
Articles by Anthony J. Olszanski, MD, RPh
Anthony J. Olszanski, MD, RPh, discusses the treatment selection process for use of cemiplimab in patients with cutaneous squamous cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Olszanski Discusses Advances in Stage III MelanomaMarch 29th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5